COVID-19, COVID-19 Acute Respiratory Distress Syndrome
Conditions
Keywords
COVID-19, ARDS
Brief summary
This phase IIb study, LEONARDO is a multicenter, randomized, double-blind, placebo- controlled, parallel group study, to assess the therapeutic efficacy and safety of Plerixafor in patients over 18 years of age, * with acute respiratory failure related to COVID-19 and * Recently admitted in ICU or equivalent structure (within 48 hours) for COVID-19 related respiratory failure * without invasive mechanical ventilation and * requiring oxygen support ≥ 5L/min to obtain a transcutaneous O2 saturation \> 94% A total of 150 participants, will be randomized in a 2:1 ratio to receive either Plerixafor (n=100) or placebo (n=50) as a continuous IV infusion for 7 days (from D1 to D8) in addition to standard of care (e.g. glucocorticoids...). Safety data will be reviewed by an independent Data and Safety Monitoring Board (DSMB) during the study.
Interventions
DRUGPlerixafor 20 MG/ML [Mozobil]
Plerixafor (Mozobil®) continuous intravenous infusion for 7 days
OTHERPlacebo
Placebo continuous intravenous infusion for 7 days
Sponsors
4Living Biotech
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female ≥ 18 years of age, * Using contraceptive consistent with local regulations regarding the methods of contraception for those participating in clinical studies * Willing and able to provide written informed consent (or provided by legally acceptable representative if he/she is present and if in line with local regulations), * Admitted in ICU within 48 hours before randomization for COVID-19 related respiratory failure. (ICU or equivalent medical structure according to country specificities e.g., Acute Respiratory Care Unit, High Dependency Care Unit if they can provide: continuous IV infusion,continuous ECG, respiratory rate, percutaneous oxygen saturation screen monitoring, high flow nasal oxygen) * Not requiring immediate (within 24-36 hours) invasive mechanical ventilation according to investigator's judgment, * Confirmed pneumoniae due to SARS-CoV-2, Laboratory-confirmed SARS-CoV-2 infection as determined by RT-PCR (in nasopharynx or throat samples) or other commercial or public health assay in any specimen, performed within 2 weeks prior to randomization, * Acute respiratory failure requiring oxygen support (≥ 5L/min) to achieve a transcutaneous oxygen saturation \> 94%, * Estimated glomerular filtration rate (eGFR) \> 50 mL/min/1.73m2 by the CKD-EPI (Chronic Kidney Disease - Epidemiology Collaboration) equation.
Exclusion criteria
* Pregnancy or breast feeding, * Anticipated transfer to another hospital, which is not a study site within 72 hours of randomisation, * Need for Invasive mechanical ventilation at time of inclusion, * Evidence of uncontrolled bacterial pneumopathy or active infection other than SARS-Cov-2 (laboratory confirmation), * Primitive pulmonary arterial hypertension, * Cardio-vascular co-morbidity: * History of vascular ischemic events (myocardial infarction or stroke) or congestive heart failure or peripheral arterial disease, * History or current significant cardiac rhythm disorders (e.g., ventricular tachycardia), * Known medical history of proven symptomatic postural hypotension, * Known cancer (solid or blood) in the last 5 previous years or previous haematological disorders (malignancies and other chronic conditions) or having received bone marrow transplant, * Inadequate haematological function defined by: * Neutrophil count \< 1.0 x 109/L, * Haemoglobin \< 9.0 g/dL (90 g/L), * Platelets \< 100 x 109/L, * Kaliemia \< 3.5 mmol/L and/or total Calcemia \< 2.2 mmol/L, * Inadequate hepatic function defined by Aspartate aminotransferase (AST) and/or Alanine Aminotransferase (ALT) \> 3 x upper limit of normal (ULN) and/or Total bilirubin \> 2 x ULN, * Patients with known allergy to Plerixafor or its excipients. * Previous (within 4 weeks) or current participation in another clinical study other than an observational study. * Patients with auto immune disease treated or not,
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To demonstrate that Plerixafor is able to reduce the need for invasive mechanical ventilation or death in severe COVID-19 patients admitted in Intensive Care Unit (ICU) | Day 1- Day 28 | Proportion of patients with need for invasive mechanical ventilation or death between randomization and D28 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the efficacy of Plerixafor compared to placebo on Mortality between randomization and D90 | Day 1-Day 90 | Percentage of death (all-cause mortality) |
| To evaluate the efficacy of Plerixafor compared to placebo on Ventilator-free days between randomization and D28 | Day 1-Day 28 | Number of Ventilator-free days |
| To evaluate the efficacy of Plerixafor compared to placebo on Duration of mechanical ventilation between randomization and D90 | Day 1-Day 90 | Duration of invasive mechanical ventilation in survivors |
| To evaluate the efficacy of Plerixafor compared to placebo on Length of ICU stay between randomization and D90 | Day 1-Day 90 | Number of ICU stay days |
| To evaluate the efficacy of Plerixafor compared to placebo on Respiratory function including FEV1, FVC, PaO2 and Transfer Lung Capacity for carbon monoxide (TLCO), 6-minute walk test | Day 1-Day 90 | Respiratory function at 3 months (FEV-1, FVC, PaO2, TLCO, 6-minute walk test) |
| To evaluate the efficacy of Plerixafor compared to placebo on Clinical improvement | Day 1, Day 8, Day 14 Day 28, Day 90 | Ordinal Scale for Clinical Improvement (Clinical improvement: 7-point ordinal scale of the WHO Master Protocol (WHO, 2020). 1: not hospitalized up to 7:death) |
| To evaluate the efficacy of Plerixafor compared to placebo on Mortality between randomization and D28 | Day 1-Day 28 | Percentage of death (all-cause mortality) |
| To evaluate the efficacy of Plerixafor compared to placebo on SpO2 status | Day 1-Day 8, Day 14, Day 28, Day 90 | Measure of SpO2 via pulse oxymetry |
| To evaluate the efficacy of Plerixafor compared to placebo on Respiratory/oxygenation status | Day 1-Day 8, Day 14, Day 28, Day 90 | Measure of Partial pressure of oxygen (PaO2), Partial pressure of carbon dioxide (PaCO2), Bicarbonate (HCO3), |
| To evaluate the efficacy of Plerixafor compared to placebo on CRP, fibrinogen and D-dimers levels | Day 1, Day 3, Day 8, Day 14, Day 28 | Blood CRP, fibrinogen, D-dimers levels |
| To evaluate the efficacy of Plerixafor compared to placebo on Safety AEs | up to Day 90 | Incidence of treatment-emergent AEs (TEAEs), serious AEs (SAEs), and AEs of special interest (AESIs), incidence of treatment on discontinuation and withdrawals due to TEAEs |
| To evaluate the efficacy of Plerixafor compared to placebo on Safety/Lab tests | up to Day 90 | Quantification of White Blood Cells count and differential, Red Blood Cells count, hemoglobin level, Mean Corpuscular Volume, Reticulocyte and Platelet counts . Blood Chemistry (Creatinine, AST, ALT, total bilirubin, Potassium, total Calcium) |
| To evaluate the efficacy of Plerixafor compared to placebo on Level of consciousness | Day 1-Day 8, Day 14, Day 28, Day 90 | Level of consciousness (Alert, Voice, Pain, Unresponsive scale) |
Countries
Bulgaria, France
Outcome results
None listed